Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

This bill increases federal funding for sickle cell disease (SCD) programs from $4.455 million annually to $8.205 million per year (2024-2028) and expands the scope of covered activities. It revises existing law to specifically include "the prevention and treatment of complications" of SCD alongside treatment itself, affecting patients with SCD and related heritable blood disorders. Key mechanisms include updating funding levels, changing contracting language to allow grants or cooperative agreements, and broadening the definition of covered services. The bill directly impacts medical research, patient care programs, and healthcare providers treating SCD patients. It aims to enhance research, surveillance, prevention, and treatment efforts for SCD and other heritable blood disorders.